Patents by Inventor Gerd Luippold

Gerd Luippold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180193427
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Inventors: Rolf GREMPLER, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd LUIPPOLD, Michael MARK
  • Publication number: 20140256624
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: January 17, 2014
    Publication date: September 11, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rolf GREMPLER, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd LUIPPOLD, Michael MARK
  • Publication number: 20140228286
    Abstract: A method of treating diabetes mellitus or a microvascular or macrovascular complication of diabetes mellitus in a patient in need thereof, the method comprising administering to the patient a compound of formula 1 wherein R1, R2, R3, and R4 are as defined in claim 1.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 14, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Gerd Luippold, Peter NICKOLAUS, Ruediger STREICHER
  • Publication number: 20130310398
    Abstract: Combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 21, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Michael MARK, Peter EICKELMANN, Gerd LUIPPOLD, Leo THOMAS
  • Patent number: 8513264
    Abstract: The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: August 20, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Mark, Peter Eickelmann, Gerd Luippold, Leo Thomas
  • Publication number: 20130109703
    Abstract: The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.
    Type: Application
    Filed: March 18, 2011
    Publication date: May 2, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Peter Eickelmann, Gerd Luippold, Michael Mark, Leo Thomas
  • Publication number: 20130035298
    Abstract: The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.
    Type: Application
    Filed: July 2, 2012
    Publication date: February 7, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Uli BROEDL, Maximilian von EYNATTEN, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd LUIPPOLD
  • Publication number: 20120283169
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: November 2, 2011
    Publication date: November 8, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rolf GREMPLER, Odd-Eric JOHANSEN, Thomas KLEIN, Gerd LUIPPOLD, Michael MARK
  • Publication number: 20110263617
    Abstract: The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.
    Type: Application
    Filed: September 8, 2009
    Publication date: October 27, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Michael Mark, Peter Eickelmann, Gerd Luippold, Leo Thomas